Expense

Sterling Bancorp Reports First Quarter 2023 Financial Results

Retrieved on: 
Monday, May 1, 2023
Banking, Professional Services, Finance, Insurance, Justice minister, Income tax, Michael J. Hsu, Asus, Life, U.S. Department of Commerce Office of Security, Classification, Comptroller, Current Expected Credit Losses, Culture, DOJ, Sterling Bancorp, Silicon Valley Bank, Risk management, U.S. Department of Justice Office of Legislative Affairs, Trust, SOX, Benefit, Sale, Compact disc, Asset, Silicon, Currency, Expense, Bargaining, Risk, F.S.B, CECL, Recovery, Webcast, Bank, Accounting Standards Codification, SBT, NOW, Signature Bank, Sterling Bank, Community Advantage Loan, Cryptocurrency, Security (finance), Pharmaceutical industry, Life insurance, Justice

Sterling Bancorp, Inc. (NASDAQ: SBT) (“Sterling” or the “Company”), the holding company of Sterling Bank and Trust, F.S.B.

Key Points: 
  • Sterling Bancorp, Inc. (NASDAQ: SBT) (“Sterling” or the “Company”), the holding company of Sterling Bank and Trust, F.S.B.
  • (the “Bank”), today reported its unaudited financial results for the first quarter ended March 31, 2023.
  • “Sterling’s first quarter of 2023 results continue the very deliberate remediation and repositioning begun in 2020.
  • Consequently, margin pressures are being witnessed here and throughout the industry.”
    Management will host a conference call on Monday, May 1, 2023 at 11:00 a.m. Eastern Time to discuss the Company’s unaudited financial results for the quarter ended March 31, 2023.

Emmaus Life Sciences Reports 2022 Financial Results and Provides Business Update

Retrieved on: 
Friday, March 31, 2023
OTCQX, Glutamine, Sickle cell disease, COVID-19, Operating cost, Travel, Expense, Research, Video game, Pharmaceutical industry, Cryptocurrency

TORRANCE, Calif., March 31, 2023 /PRNewswire/ -- Emmaus Life Sciences, Inc. (OTCQX: EMMA), a commercial-stage biopharmaceutical company and leader in the treatment of sickle cell disease, today reported its results of operation for the year ended December 31, 2022 and an update on recent activities.

Key Points: 
  • TORRANCE, Calif., March 31, 2023 /PRNewswire/ -- Emmaus Life Sciences, Inc. (OTCQX: EMMA), a commercial-stage biopharmaceutical company and leader in the treatment of sickle cell disease, today reported its results of operation for the year ended December 31, 2022 and an update on recent activities.
  • Net revenues for the year ended December 31, 2022 were $18.4 million, compared to $20.6 million for 2021.
  • Operating loss for the year ended December 31, 2022 was $6.6 million, compared with $6.1 million in 2021 due primarily to the decrease in net revenues.
  • At December 31, 2022, the company had cash and cash equivalents of $2.0 million, compared with $2.3 million at December 31, 2021.

Altus Power, Inc. Announces Fourth Quarter and Full Year 2022 Financial Results

Retrieved on: 
Thursday, March 30, 2023
Alternative Energy, Energy, Other Energy, Utilities, Equipment, ASC, Disposal, Bank statement, Altus, NMCA, Redmi Note 11, Form 10-K, GAAP, Interest expense, Accounting, REC, Entity, Alignment, Mergers and acquisitions, Monte Carlo, Expense, EBITDA, Retirement, PAR, Acquisition, Accretion expense, Depreciation, Professional, Samsung Galaxy Note 20, Earnout, Growth, PPA, NYSE, Pharmaceutical industry, Cryptocurrency, Video game, Renewable energy, Security (finance), Insurance, Bookkeeping, Bank, Sewage treatment

Altus Power, Inc. (NYSE: AMPS) (“Altus Power” or the “Company”), the premier independent commercial-scale clean electrification company, today announced its financial results for fourth quarter and full year 2022.

Key Points: 
  • Altus Power, Inc. (NYSE: AMPS) (“Altus Power” or the “Company”), the premier independent commercial-scale clean electrification company, today announced its financial results for fourth quarter and full year 2022.
  • Fourth quarter 2022 GAAP net income totaled $67.1 million, compared to $14.5 million for the same period last year.
  • Adjusted EBITDA* during the fourth quarter of 2022 was $16.6 million, compared to $12.9 million for the fourth quarter of 2021, a 29% increase.
  • Altus Power ended the fourth quarter of 2022 with $193.0 million in cash and $664.6 million of total debt.

MAIA Biotechnology Reports Full Year 2022 Financial Results and Provides Corporate Update

Retrieved on: 
Friday, March 24, 2023
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, MAIA, Society, Hepatocellular carcinoma, Cancer, Immunotherapy, G&A, Research, NSCLC, Cell, Expense, Society for Immunotherapy of Cancer, Patient, Administration, Liver, Research and development, R, FDA, Death, IND, NYSE, HCC, Safety, Pharmaceutical industry, Vaccine, Cryptocurrency

MAIA Biotechnology, Inc., (NYSE: MAIA) (“MAIA”, the “Company”), a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer, today reported financial results for the full year ended December 31, 2022, and provided a corporate update.

Key Points: 
  • MAIA Biotechnology, Inc., (NYSE: MAIA) (“MAIA”, the “Company”), a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer, today reported financial results for the full year ended December 31, 2022, and provided a corporate update.
  • The Company has demonstrated encouraging preclinical results in colorectal, liver, and small cell lung cancer models.
  • R&D expenses included approximately $0.9 million and $0.9 million of non-cash stock compensation expense in the year 2022 and 2021, respectively.
  • G&A expenses included approximately $1.4 million and $1.8 million of non-cash stock compensation expense in the years ended December 31, 2022, and 2021, respectively.

Surrozen Provides Fourth Quarter and Full Year 2022 Financial Results and Update on Clinical Pipeline and Corporate Progress

Retrieved on: 
Wednesday, March 22, 2023
Insurance, Patent, Partnership, Therapy, Liver disease, Clinical trial, Consonance and dissonance, Lead, Research, Retina, Sale, Ulcerative colitis, Interest, Boehringer Ingelheim, Development, ATM, Regeneration, Expense, Alcoholic hepatitis, Investment, Administration, SAN, Retinopathy, Growth, Chronic liver disease, Collaboration, Guggenheim Partners, Pharmaceutical industry, Cryptocurrency, Financial adviser, WNT

The company anticipates a reduction in operating expenses, excluding non-cash and non-recurring charges of approximately 15% in 2023 compared to 2022.

Key Points: 
  • The company anticipates a reduction in operating expenses, excluding non-cash and non-recurring charges of approximately 15% in 2023 compared to 2022.
  • Surrozen executed a partnership with Boehringer Ingelheim in the fourth quarter of 2022 to develop a Wnt agonist, SZN-413, for the treatment of people with retinal diseases.
  • In the fourth quarter of 2022, Surrozen entered into a securities purchase agreement with entities affiliated with Consonance Capital Management LP (collectively Consonance).
  • Surrozen will host an investor conference call and live audio webcast today at 4:30 PM ET to provide a corporate and pipeline update.

Nubeva Announces Strong Financial Results for Fiscal Q3 2023

Retrieved on: 
Wednesday, March 22, 2023
Expense, OTCQB, Interview, SAN, Bank statement, SEDAR

SAN JOSE, Calif., March 22, 2023 (GLOBE NEWSWIRE) -- Nubeva Technologies (TSX-V: NBVA, OTCQB: NBVAF)(“Nubeva” or the “Company”) , today reported strong year over year results in Revenue, Gross Margins, Net Earnings and Expenses for the first 9 months of its fiscal year as well as its most recent 3-month period.

Key Points: 
  • SAN JOSE, Calif., March 22, 2023 (GLOBE NEWSWIRE) -- Nubeva Technologies (TSX-V: NBVA, OTCQB: NBVAF)(“Nubeva” or the “Company”) , today reported strong year over year results in Revenue, Gross Margins, Net Earnings and Expenses for the first 9 months of its fiscal year as well as its most recent 3-month period.
  • "We are thrilled to report such outstanding results," said Randy Chou, CEO of Nubeva.
  • In addition to solid revenue growth, Nubeva also reported that plans to be cash flow positive in 2023 , operating expenses are being effectively managed, and the pipeline is growing.
  • The company's financial statements and management's discussion and analysis can be found on SEDAR .

LiqTech International Announces Financial Results for Fourth Quarter and Full Year 2022

Retrieved on: 
Wednesday, March 22, 2023
DPF, COVID-19, DKK, USD, Convertible, EUR, Expense, Swimming, MEG, Growth, Silicon, Hand, Cryptocurrency, Management, Bank

BALLERUP, Denmark, March 22, 2023 /PRNewswire/ -- LiqTech International, Inc. (NASDAQ: LIQT) ("LiqTech"), a clean technology company that manufactures and markets highly specialized filtration technologies, today announced its financial results for the fourth quarter and fiscal year ended December 31, 2022.

Key Points: 
  • BALLERUP, Denmark, March 22, 2023 /PRNewswire/ -- LiqTech International, Inc. (NASDAQ: LIQT) ("LiqTech"), a clean technology company that manufactures and markets highly specialized filtration technologies, today announced its financial results for the fourth quarter and fiscal year ended December 31, 2022.
  • Q4 2022 revenue of $4.0 million, a 22% sequential increase from Q3 2022.
  • Operating expense of $2.3 million (excluding restructuring costs), down 37% from Q4 2021 and $0.1 million compared to Q3 2022.
  • Compared to the third quarter of 2022, our sequential quarter-end cash balance only decreased by $1.0 million.

eFFECTOR Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update

Retrieved on: 
Wednesday, March 8, 2023
Research and development, Effector, Cell, STRI Group, QW, Investment, NSCLC, University of California, San Francisco, KICKSTART, Pembrolizumab, MNK, ER, Lung cancer, DARPA, Therapy, PD-L1, Safety, Administration, San Francisco, Fulvestrant, R, COVID-19, University, Clinical trial, Expense, Cancer, CBR, Research, Net operating loss, Patient, PRS, G&A, Messenger, ORR, Cryptocurrency, Pharmaceutical industry, Vaccine, COVID

SOLANA BEACH and REDWOOD CITY, Calif., March 08, 2023 (GLOBE NEWSWIRE) -- eFFECTOR Therapeutics, Inc. (NASDAQ: EFTR), a leader in the development of selective translation regulator inhibitors (STRIs) for the treatment of cancer, today reported financial results for the fourth quarter and year ended December 31, 2022 and provided a corporate update.

Key Points: 
  • Revenue: Revenue was $0.7 million for the quarter ended December 31, 2022, compared to approximately $0.3 million for the same quarter of 2021.
  • Research and Development (R&D) Expenses: R&D expenses were $6.6 million for the quarter ended December 31, 2022, compared to $6.4 million for the same quarter of 2021.
  • General and Administrative (G&A) Expenses: G&A expenses were $2.7 million for the quarter ended December 31, 2022, compared to $6.3 million for the same quarter of 2021.
  • Other Income (Expense): Other expense was $0.5 million for the quarter ended December 31, 2022 and other income for the quarter ended December 31, 2021 was $31.5 million.

vTv Therapeutics Announces 2022 Fourth Quarter and Full Year Financial Results and Provides Corporate Update

Retrieved on: 
Monday, March 6, 2023
General counsel, Novo Nordisk, Receptor (biochemistry), General Administration of Sport of China, Type 2 diabetes, III, FDA, Therapy, Administration, VTV, Research and development, R, Insulin, Clinical trial, Expense, Patient, G&A, Acceleration, Pharmaceutical industry, Security (finance), Management, Cryptocurrency, Lithium, Reinsurance, T1D

“We have made a great deal of progress since I joined vTv early in the second half of 2022,” said Paul Sekhri, Chief Executive Officer of vTv.

Key Points: 
  • “We have made a great deal of progress since I joined vTv early in the second half of 2022,” said Paul Sekhri, Chief Executive Officer of vTv.
  • On December 8, 2022, the Company appointed Steven Tuch as Executive Vice president and Chief Financial Officer.
  • Net Loss: Net loss attributable to vTv shareholders for the year ended December 31, 2022, was $19.2 million or $0.26 per basic share.
  • Net loss attributable to vTv shareholders for the comparable period a year ago was $13.0 million or $0.21 per basic share.

Bird Announces Fourth Quarter and Full Year 2022 Financial Results

Retrieved on: 
Friday, March 10, 2023
Public Transport, Alternative Vehicles, Fuels, EV, Electric Vehicles, Automotive, Vehicle Technology, Transport, Automotive Manufacturing, Manufacturing, Motorcycles, Birds Canada, Acquisition, Expense, Adjustment, NYSE, Economics, Apollo, Financial result, City, CFO, Cryptocurrency, Renting, Insurance, Reinsurance, Bookkeeping, Commercial property, Bird

Bird Global, Inc. ("Bird" or the "Company") (NYSE: BRDS), a leader in environmentally friendly electric transportation, today announced financial results for the fourth quarter and full year ended December 31, 2022.

Key Points: 
  • Bird Global, Inc. ("Bird" or the "Company") (NYSE: BRDS), a leader in environmentally friendly electric transportation, today announced financial results for the fourth quarter and full year ended December 31, 2022.
  • In the fourth quarter, we saw dramatically improved gross margins and reduced operating expenses, which position Bird to generate positive Adjusted EBITDA and Free Cash Flow in 2023."
  • Fourth Quarter Ended December 31, 2022 Financial Results
    Revenue was $69.7 million compared to $49.5 million in the same period in 2021 ("the prior year period").
  • Revenue in the fourth quarter included $28.8 million unredeemed preloaded wallet balances from prior periods.